Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
39.103,22 +486,12 (+1,26%) EUR/USD
1,0831 +0,0004 (+0,03%) Bitcoin EUR
64.100,09 -426,55 (-0,66%) CMC Crypto 200
1.510,49 +7,83 (+0,52%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Dopo ore:
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:
